Related Experiment Video

Updated: May 2, 2026

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
10:44

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

12.9K

Selective inhibition of BET bromodomain epigenetic signalling interferes with the bone-associated tumour vicious

François Lamoureux1, Marc Baud'huin2, Lidia Rodriguez Calleja3

  • 11] INSERM, UMR 957, Équipe labellisée ligue 2012, 1 Rue Gaston Veil, Nantes 44035, France [2] Physiopathologie de la Résorption Osseuse et Thérapie des Tumeurs Osseuses Primitives, Université de Nantes, Nantes Atlantique Universités, EA3822, 1 Rue Gaston Veil, Nantes 44035, France [3].

Nature Communications
|March 21, 2014
PubMed

Insights

BET bromodomain inhibition using JQ1 effectively targets bone tumours and resorption. This strategy reduces osteosarcoma cell viability and inhibits both osteoblast and osteoclast differentiation, offering a novel therapeutic approach for bone cancers.

Area of Science:

  • Oncology
  • Bone Biology
  • Epigenetics

Background:

  • Bone resorption and primary bone tumours form a detrimental cycle.
  • Targeting this cycle is crucial for effective cancer therapy.
  • BET bromodomain proteins are implicated in this vicious cycle.

Purpose of the Study:

  • To investigate BET bromodomain inhibition as a therapeutic strategy for bone tumours.
  • To evaluate the effects of JQ1 on osteosarcoma cells and bone cells.
  • To elucidate the molecular mechanisms underlying JQ1's action.

Main Methods:

  • Treatment of osteosarcoma cells with JQ1 in vitro and in vivo.
  • Assessment of cell viability and differentiation markers.
  • Analysis of gene expression and protein localization (MYC, RUNX2, BRD4, RANKL, NFATC1).

Main Results:

  • JQ1 reduced osteosarcoma cell viability and inhibited osteoblastic differentiation.
  • JQ1 treatment led to transcriptional silencing of MYC and RUNX2 via BRD4 depletion.
  • JQ1 inhibited osteoclast differentiation by disrupting BRD4-dependent RANKL activation of NFATC1.

Conclusions:

  • BET bromodomain inhibition is a promising strategy against bone tumours and metastasis.
  • JQ1 effectively inhibits osteoblast and osteoclast differentiation.
  • Targeting BRD4 offers a simultaneous approach to disrupt the bone tumour-resorption cycle.

More Related Videos

Inducible and Reversible Dominant-negative DN Protein Inhibition08:35

Inducible and Reversible Dominant-negative DN Protein Inhibition

Published on: January 7, 2019

7.7K
In Vitro Differentiation Model of Human Normal Memory B Cells to Long-lived Plasma Cells10:26

In Vitro Differentiation Model of Human Normal Memory B Cells to Long-lived Plasma Cells

Published on: January 20, 2019

12.3K

Related Concept Videos

Epigenetic Regulation01:37

Epigenetic Regulation

Epigenetic changes alter the physical structure of the DNA without changing the genetic sequence and often regulate whether genes are turned on or off. This regulation ensures that each cell produces only proteins necessary for its function. For example, proteins that promote bone growth are not produced in muscle cells. Epigenetic mechanisms play an essential role in healthy development. Conversely, precisely regulated epigenetic mechanisms are disrupted in diseases like cancer.
X-chromosome...
3.5K
Epigenetic Regulation01:46

Epigenetic Regulation

Epigenetic mechanisms play an essential role in healthy development. Conversely, precisely regulated epigenetic mechanisms are disrupted in diseases like cancer.
28.7K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.0K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.0K
Negative Regulator Molecules01:23

Negative Regulator Molecules

Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
32.1K